PA8534601A1 - Activadores de glucocinasa del tipo isoindolin-1-ona - Google Patents

Activadores de glucocinasa del tipo isoindolin-1-ona

Info

Publication number
PA8534601A1
PA8534601A1 PA20018534601A PA8534601A PA8534601A1 PA 8534601 A1 PA8534601 A1 PA 8534601A1 PA 20018534601 A PA20018534601 A PA 20018534601A PA 8534601 A PA8534601 A PA 8534601A PA 8534601 A1 PA8534601 A1 PA 8534601A1
Authority
PA
Panama
Prior art keywords
isoindolin
ona
type
glucocinase
activators
Prior art date
Application number
PA20018534601A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Richard Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8534601A1 publication Critical patent/PA8534601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
PA20018534601A 2000-12-13 2001-12-10 Activadores de glucocinasa del tipo isoindolin-1-ona PA8534601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13

Publications (1)

Publication Number Publication Date
PA8534601A1 true PA8534601A1 (es) 2002-08-26

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018534601A PA8534601A1 (es) 2000-12-13 2001-12-10 Activadores de glucocinasa del tipo isoindolin-1-ona

Country Status (35)

Country Link
US (1) US6482951B2 (enExample)
EP (1) EP1349856B1 (enExample)
JP (1) JP4021766B2 (enExample)
KR (1) KR100520651B1 (enExample)
CN (1) CN1247574C (enExample)
AT (1) ATE297922T1 (enExample)
AU (2) AU2002238415B2 (enExample)
BG (1) BG107903A (enExample)
BR (1) BR0116169A (enExample)
CA (1) CA2430579C (enExample)
CY (1) CY1105587T1 (enExample)
CZ (1) CZ20031882A3 (enExample)
DE (1) DE60111570T2 (enExample)
DK (1) DK1349856T3 (enExample)
EG (1) EG24358A (enExample)
ES (1) ES2243578T3 (enExample)
HR (1) HRP20030450B1 (enExample)
HU (1) HUP0400587A3 (enExample)
IL (2) IL156264A0 (enExample)
MA (1) MA26973A1 (enExample)
MX (1) MXPA03005170A (enExample)
MY (1) MY136741A (enExample)
NO (1) NO325810B1 (enExample)
NZ (1) NZ526236A (enExample)
PA (1) PA8534601A1 (enExample)
PE (1) PE20020593A1 (enExample)
PL (1) PL366006A1 (enExample)
PT (1) PT1349856E (enExample)
RS (1) RS50933B (enExample)
RU (1) RU2249590C2 (enExample)
SI (1) SI1349856T1 (enExample)
SK (1) SK8732003A3 (enExample)
TW (1) TWI294876B (enExample)
UY (1) UY27069A1 (enExample)
WO (1) WO2002048106A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2005113713A (ru) 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
ATE374768T1 (de) 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2007530631A (ja) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
CA2560689C (en) 2004-04-02 2011-03-01 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
JPWO2007026761A1 (ja) * 2005-08-31 2009-03-12 アステラス製薬株式会社 チアゾール誘導体
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
CA2628259A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
CN101316837A (zh) 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的吡咯酮类
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2116533B1 (en) 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
CA2712998A1 (en) * 2008-01-24 2009-07-30 Stefan Bender Beta-amino acid derivatives for treatment of diabetes
HUE025224T2 (en) 2008-04-28 2016-02-29 Kyorin Seiyaku Kk Ciklopentilakrilsav amide derivatives
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators
PE20110303A1 (es) * 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
EP3199623B1 (en) 2010-03-31 2021-07-28 The Scripps Research Institute Reprogramming cells
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
TWI704143B (zh) * 2013-05-27 2020-09-11 瑞士商赫孚孟拉羅股份公司 新穎3,4-二氫-2h-異喹啉-1-酮及2,3-二氫異吲哚-1-酮化合物
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CA3119509A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0832065B1 (en) * 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
ES2226811T3 (es) 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
DE60113247T2 (de) 2000-05-03 2006-06-22 F. Hoffmann-La Roche Ag Hydantoin-enthaltende glucokinase aktivatoren
ATE280163T1 (de) 2000-05-08 2004-11-15 Hoffmann La Roche Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren

Also Published As

Publication number Publication date
TWI294876B (en) 2008-03-21
IL156264A0 (en) 2004-01-04
NZ526236A (en) 2004-12-24
NO20032674L (no) 2003-06-12
MY136741A (en) 2008-11-28
KR20030064817A (ko) 2003-08-02
YU47703A (sh) 2006-05-25
EG24358A (en) 2009-03-04
EP1349856B1 (en) 2005-06-15
EP1349856A2 (en) 2003-10-08
BR0116169A (pt) 2003-12-23
HRP20030450B1 (en) 2006-02-28
CA2430579C (en) 2010-01-26
WO2002048106A2 (en) 2002-06-20
HUP0400587A3 (en) 2011-03-28
RU2249590C2 (ru) 2005-04-10
SK8732003A3 (en) 2004-04-06
KR100520651B1 (ko) 2005-10-11
DE60111570T2 (de) 2006-05-11
AU2002238415B2 (en) 2007-01-04
ATE297922T1 (de) 2005-07-15
CN1481382A (zh) 2004-03-10
US20020082260A1 (en) 2002-06-27
RS50933B (sr) 2010-08-31
PE20020593A1 (es) 2002-07-06
IL156264A (en) 2010-11-30
DK1349856T3 (da) 2005-10-17
ES2243578T3 (es) 2005-12-01
DE60111570D1 (de) 2005-07-21
MXPA03005170A (es) 2003-09-22
NO20032674D0 (no) 2003-06-12
MA26973A1 (fr) 2004-12-20
CA2430579A1 (en) 2002-06-20
CY1105587T1 (el) 2010-07-28
AU3841502A (en) 2002-06-24
BG107903A (bg) 2004-02-27
PT1349856E (pt) 2005-09-30
CN1247574C (zh) 2006-03-29
WO2002048106A3 (en) 2002-11-28
HUP0400587A2 (hu) 2004-06-28
HRP20030450A2 (en) 2005-04-30
US6482951B2 (en) 2002-11-19
UY27069A1 (es) 2002-07-31
SI1349856T1 (en) 2005-10-31
NO325810B1 (no) 2008-07-21
CZ20031882A3 (cs) 2003-12-17
PL366006A1 (en) 2005-01-24
JP2004521095A (ja) 2004-07-15
HK1063314A1 (en) 2004-12-24
JP4021766B2 (ja) 2007-12-12

Similar Documents

Publication Publication Date Title
PA8534601A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
PA8584001A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
ECSP014067A (es) Activadores de fenil glucoquinasa para-aril o heterociclico sustituida
ATE461217T1 (de) Glp-1-verbindungen
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
AR046877A1 (es) Muteinas del factor de crecimiento de fibroblastos 21
MY152164A (en) Extending time to disease progression or survival in cancer patients
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
AR109263A2 (es) Composición que comprende moxidectina
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
EP1988915A4 (en) METHOD FOR MODULATING CELLULAR ACTIVITY AND AGENTS FOR USE THEREFROM
ECSP034651A (es) Activadores de glucocinasa isoindolin-1-ona
UY26690A1 (es) Activadores heteroaromáticos de la alquinil - fenil glucoquinasa
AR046641A1 (es) Uso del (+)-(2s, 3s)-2-(3-clorofenil)-3,5,5-trimetil-2-morfolinol
AR051035A1 (es) Uso de epotilonas en el tratamiento de metastasis en hueso
UY27766A1 (es) Combinacion de insulina y un derivado de tiazolidindiona y uso de la misma para tratar la diabetes
CR7516A (es) Tratamiento de la gastroparesia